Adtalem Q2 revenue up 12.4%, beats estimates

Reuters
01/29
Adtalem <a href="https://laohu8.com/S/QTWO">Q2</a> revenue up 12.4%, beats estimates

Overview

  • Healthcare educator's Q2 revenue rose 12.4% yr/yr, beating analyst expectations

  • Adjusted EPS grew 34.3% yr/yr

  • Company announced new $750 mln share repurchase program

Outlook

  • Adtalem maintains fiscal year 2026 revenue guidance at $1,900 mln to $1,940 mln

  • Company raises fiscal year 2026 adjusted EPS guidance to $7.80-$8.00

  • Adtalem to host Investor Day on February 24, 2026

Result Drivers

  • ENROLLMENT GROWTH - Total student enrollment increased 6.3% YoY, marking the tenth consecutive quarter of growth, driven by Walden University's 13% enrollment rise

  • WALDEN UNIVERSITY PERFORMANCE - Walden University achieved a 13% YoY increase in enrollment, contributing to a 27% revenue growth

  • CHAMBERLAIN UNIVERSITY INITIATIVES - Chamberlain University continued pre-licensure BSN enrollment growth

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$503.40 mln

$488.73 mln (4 Analysts)

Q2 Net Income

$76.40 mln

Q2 Adjusted EBITDA

Beat

$154.90 mln

$139.09 mln (3 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the miscellaneous educational service providers peer group is "buy."

  • Wall Street's median 12-month price target for Adtalem Global Education Inc is $166.50, about 44.5% above its January 27 closing price of $115.22

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nBw22rV2Sa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10